Sunesis shares tumble after failed leukemia drug study

An experimental leukemia drug by Sunesis Pharmaceuticals Inc. failed a late-stage clinical trial, the company said Monday, sending its stock spiraling in pre-market trading. Shares of South San Francisco-based Sunesis fell $4.72 - or more than 70 percent - to $1.92 per share.

http://ift.tt/ZpzvYF